ATP-Based Chemotherapy Response Assay in Primary or Recurrent Ovarian and Peritoneal Cancer.
10.3349/ymj.2014.55.6.1664
- Author:
Maria LEE
1
;
Sang Wun KIM
;
Eun Ji NAM
;
Hanbyoul CHO
;
Jae Hoon KIM
;
Young Tae KIM
;
Sunghoon KIM
Author Information
1. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Adenosine triphosphate;
cell death;
drug therapy;
combination;
ovarian cancer
- MeSH:
Adenocarcinoma, Clear Cell/*drug therapy/metabolism/pathology;
Adenosine Triphosphate/*metabolism;
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Camptothecin/administration & dosage/analogs & derivatives;
Carboplatin/therapeutic use;
Cisplatin/administration & dosage;
Drug Resistance, Neoplasm;
Drug Screening Assays, Antitumor/methods;
Female;
Humans;
Ifosfamide/administration & dosage;
Middle Aged;
Neoplasm Recurrence, Local/*drug therapy;
Neoplasms, Glandular and Epithelial/*drug therapy/metabolism/pathology;
Ovarian Neoplasms/*drug therapy/metabolism/pathology;
Paclitaxel/therapeutic use;
Peritoneal Neoplasms/*drug therapy/metabolism/pathology;
Predictive Value of Tests;
Sensitivity and Specificity;
Taxoids/administration & dosage
- From:Yonsei Medical Journal
2014;55(6):1664-1671
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To investigate chemosensitivity with an adenosine triphosphate-based chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer according to tumor histology, grade, and disease status. MATERIALS AND METHODS: One hundred specimens were collected during primary or secondary debulking from 67 patients with primary ovarian cancer, 24 patients with recurrent ovarian cancer, 5 patients with primary peritoneal cancer, and 4 patients with recurrent peritoneal cancer; samples were collected between August 2006 and June 2009. Tumor cells were isolated and cultured for 48 hours in media containing chemotherapy. The chemosensitivity index (CI) was calculated as 300 minus the sum of the cell death rate at 0.2x, 1x, and 5x drug concentrations, and the CI values were compared. RESULTS: CI values were obtained from 93 of 100 patients. The most active agents against primary disease were ifosfamide and paclitaxel. For primary serous adenocarcinoma, paclitaxel and irinotecan were the most active, followed by ifosfamide. For clear cell carcinoma, ifosfamide was the most active, followed by paclitaxel and irinotecan. Although not statistically significant, the CIs of cisplatin, carboplatin, paclitaxel, and docetaxel decreased as tumor grade increased. In 14 cases of recurrent disease, paclitaxel was the most active, followed by ifosfamide and cisplatin. CONCLUSION: Ifosfamide and paclitaxel were the most active drugs for primary and recurrent disease. Therefore, we recommend further clinical studies to confirm the efficacy of paclitaxel, ifosfamide, and cisplatin combination chemotherapy for recurrent and primary ovarian cancer.
